This study tests a medicine called povetacicept in adults with certain kidney diseases, including IgA nephropathy, membranous nephropathy, lupus nephritis, and ANCA-associated vasculitis. These diseases are related to autoantibodies, which are proteins made by the immune system that mistakenly attack the body. Participants will get povetacicept every 4 weeks for 6 months, with an option to extend treatment for up to another year.
Key Points:
- Treatment lasts 6 months, with possible extensions up to a year.
- Participants need a confirmed diagnosis of one of the specified kidney diseases.
- Previous treatments like B cell or anti-BAFF therapies may disqualify you.
To join, you must have a confirmed diagnosis of one of the diseases mentioned and meet other specific health criteria. If you've had other kidney diseases or certain infections, you might not be eligible. Your kidney function must be above a certain level, and you shouldn't have had certain treatments recently. This study aims to see if povetacicept is safe and helpful. Always consult your doctor before deciding to participate.